Released Sep 14, 2023, after the close
10-Q filed Sep 14, 2023, 45 days after period end · 0001654954-23-011889
Q3 2023 · 10-Q
Revenue$4.58M$4.58M −4.1% vs Q3 2022+0.3% vs Q2 2023
Net Income$526.24K$526.24K +82.7% vs Q3 2022+30.0% vs Q2 2023
EPS, diluted—
Gross Profit$1,550,007+18.1%
Operating Income$460,466+24.6%
Operating Cash Flow$956,765−13.5%
Free Cash Flowderived$956,765−13.3%
Margins · derived
Gross margin33.9%+6.4 pt vs Q3 2022
Operating margin10.1%+2.3 pt vs Q3 2022
Net margin11.5%+5.5 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $4.58M | $4.77M | $4.99M | $6.28M |
| Net Income | $526.24K | $288.03K | $2.28M | $692.11K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR